In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Shiman Hu 胡诗曼Department of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-0939-2130 Jiaxian LiuDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0009-0008-4198-6706 Jiaqi ZhouShenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-9285-8914 Jiaohua ChenDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-5985-8341 Tiantian QinDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0003-3290-180X Yi Ching Esther WanDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-5916-3336 Xiaoxuan ZhuDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-1664-8034 Danyi WangDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.
Chuting ShaoDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.
Yabin ChenDepartment of Surgery, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-6914-9266 Xin WangDepartment of Surgery, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Junhong HanDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3371-8698 Hoi Leong Xavier WongSchool of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.ORCID 0000-0002-2460-4808 Haojie JinState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-9295-1951 Mo ChenState Key Laboratory of Molecular Oncology, School of Basic Sciences, Tsinghua University, Beijing, China.ORCID 0000-0002-6647-8483 Qing LiState Key Laboratory of Protein and Plant Gene Research, School of Life Sciences and Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.ORCID 0000-0003-0251-9159 Yogen SaunthararajahDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-9757-1031 Haiyun GanShenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.ORCID 0000-0002-0293-8778 Kui Ming Chan 陈居明Department of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-6430-3340 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Cancer progression is driven by the accumulation of DNA mutations and aberrant gene regulation. Recent studies have demonstrated that multiple H3 mutations serve as drivers of tumorigenesis. However, the role and significance of various cancer-associated histone H2B mutations in cancer development remain unknown. Here, we investigate H2BE113K, a missense mutation of histone H2B predominantly found in patients with breast cancer. We show that H2BE113K promotes colony formation in breast cancer. Notably, transcriptomic analysis reveals differential expression of genes in various cancer pathways in H2BE113K cells. The loci with elevated gene expression display increased chromatin accessibility, accompanied by H2BE113K enrichment. Depletion of
Indexed as
Breast NeoplasmsChromatinHistonesMutationMutation, MissenseAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisChromatinHistones
Identifiers
PMID42430466
PMCPMC13353378
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390